Merck exceeded third-quarter earnings and revenue expectations, driven by strong sales of its immunotherapy drug Keytruda and its newer injectable form, Qlex, which posted $830 million in sales—the highest since its 2025 launch. The company raised its adjusted profit forecast to $2.77-$2.82 per share, up from $2.66-$2.76, despite a $400 million one-time charge related to a licensing deal. Merck also narrowed its 2026 revenue guidance to $66.8-$67.3 billion. The success of Qlex supports Merck's strategy to maintain Keytruda's market share amid upcoming patent expirations in 2028. Other products like Winrevair and Gardasil also showed strong sales growth, contributing to overall revenue of $18.09 billion for the quarter, a 5% increase year-over-year.
Merck's market capitalization stands at $347.70 billion as of Oct 29, 2026, 17:41 WIB, reflecting its strong position in the health sector. The stock price on Pluang is $144.47, up 2.37% for the day, with a dividend yield of 2.41%. Trading volume reached 8,193,716 shares, showing active investor interest coinciding with the company's raised profit outlook and robust sales performance.
Moderna's stock climbed 4% after strong Phase 3 melanoma vaccine trial results, despite a downgrade from William Blair citing valuation concerns after a 636% yearly gain. The trial showed Moderna and Merck's vaccine reduced melanoma recurrence risk b...
Eli Lilly, Merck, and Gilead Sciences are set to report their Q3 2026 earnings on October 29, with Eli Lilly facing lowered EPS estimates amid strong GLP-1 drug demand, Merck dealing with tough comparisons for its cancer drug Keytruda, and Gilead man...
The global CRISPR market is forecasted to grow from $3.48 billion in 2026 to $6.12 billion by 2031, at a CAGR of 12%. Growth is fueled by expanding use in drug discovery, gene therapy, precision medicine, and agriculture, alongside technological adva...
Moderna's stock fell about 7.4% following the release of Phase 3 trial data for its experimental cancer vaccine, intismeran, developed with Merck. The results tempered investor enthusiasm, reflecting that expectations had been very high. Merck's shar...
Moderna's stock fell 7% after its personalized melanoma vaccine, despite meeting its primary goal in a late-stage trial, showed less impact on distant cancer spread than earlier studies suggested. This has led investors to reassess the commercial pot...
